Calvarial Doughnut Lesions With Bone Fragility, With or Without Spondylometaphyseal Dysplasia (CDL/CDLSMD)

Calvarial doughnut lesions with bone fragility, with or without spondylometaphyseal dysplasia (CDL/CDLSMD) is a genetic bone disease. People are born with a change (variant) in a bone gene. Because of this, their bones are weaker than normal. They break more easily, often from childhood. On X-rays or CT scans, round, ring-like spots appear in the skull bones that look like a doughnut. Some people have only weak bones and skull “doughnut” spots. Others also have a growth-plate problem called spondylometaphyseal dysplasia. This can cause short height, bent long bones, and vertebral (spine) changes from birth or early life. The condition is usually passed in families in an autosomal dominant way (one changed gene copy is enough). The main known gene is SGMS2, which makes an enzyme (sphingomyelin synthase 2) important for bone mineralization. Very rarely, a different gene (IFITM5) has been linked to a similar picture. Orpha+4PMC+4JCI Insight+4

Calvarial doughnut lesions with bone fragility (CDL) is a very rare genetic bone condition. People with CDL have weaker bones that break more easily (fragility) and special ring-shaped spots in the skull bones that look like a “doughnut” on X-ray. In some families, the condition also includes spine and long-bone growth changes called “spondylometaphyseal dysplasia,” leading to short height and spine deformity. The main known cause is a change (pathogenic variant) in the SGMS2 gene, which makes the enzyme sphingomyelin synthase-2. This enzyme helps make sphingomyelin, a lipid that is important for healthy cell membranes and bone mineralization; when it does not work properly, bone becomes fragile from early life. Reported features include low bone mineral density, fractures in childhood (sometimes from birth in the severe form), cranial “doughnut” lesions, and occasionally dental problems or even glaucoma. Inheritance is autosomal dominant (a single changed copy can cause the disorder). Because CDL is ultra-rare, there are no drugs “approved for CDL,” so care follows best practices for childhood-onset osteoporosis/fragility under specialist teams. PMC+2NCBI+2

Other names

Doctors and papers may also use these names for the same spectrum:

• Calvarial doughnut lesions–bone fragility syndrome

• Calvarial doughnut lesions with bone fragility (CDL)

• CDL with or without spondylometaphyseal dysplasia (CDLSMD)

• SGMS2-related bone fragility spectrum disorder

• Osteoporosis with calvarial doughnut lesions (older wording)

• Familial calvarial doughnut lesions (when it runs in families) MDPI+2JCI Insight+2

Types

Because the same gene can cause milder or more severe disease, clinicians often describe two ends of a spectrum:

1. Milder form (CDL): Childhood-onset low bone density with multiple fractures and the classic skull “doughnut” lesions. Height may be near normal; long bones are usually not very deformed. PMC+1

2. Severe form (CDLSMD): Symptoms start very early (even at birth). There can be many fractures, short stature, bent long bones, and clear changes at the ends of long bones and the spine (spondylometaphyseal dysplasia). Skull may be more sclerotic (dense). ESPE Yearbook+1

Causes

Important note: The root cause is genetic. Below are 20 “causes or causal factors” covering gene changes and known biological effects that lead to the clinical picture.

1. Pathogenic variants in SGMS2 (overall): The key cause in most families. PMC

2. SGMS2 c.148C>T (p.Arg50) nonsense variant:* Recurrent in several families; often milder CDL. Wikipedia+1

3. SGMS2 c.185T>G (p.Ile62Ser) missense: Often linked with the severe CDLSMD end. ESPE Yearbook

4. SGMS2 c.191T>G (p.Met64Arg) missense: Also linked with severe neonatal-onset fragility and SMD. ESPE Yearbook

5. Other rare SGMS2 variants under study: New variants continue to be reported as more families are tested. ScienceDirect+1

6. Autosomal dominant inheritance: One altered copy is enough to cause disease. NCBI+1

7. Defective sphingomyelin synthesis in bone cells: SGMS2 encodes sphingomyelin synthase-2; disturbance affects bone mineralization. PMC+1

8. Impaired mineralization of bone matrix: Leads to low bone mineral density and fractures. JCI Insight

9. Altered bone material properties (quality): Bone becomes mechanically weaker, not just less dense. JCI Insight

10. Cortical thinning and trabecular changes: Seen in imaging/biopsy in reported families. Wikipedia

11. Abnormal calvarial remodeling: Creates the ring-like (doughnut) skull lesions. Radiopaedia

12. Early vertebral fragility: Leads to compression fractures in the spine. JCI Insight

13. Cranial osteosclerosis in some patients: Very dense skull bones can accompany the lesions. NCBI

14. Spondylometaphyseal dysplasia changes (severe end): Growth-plate and vertebral involvement increase fragility. ESPE Yearbook

15. Rare IFITM5 variant (p.N48S): Reported once; shows a similar phenotype. Wikipedia

16. Possible neurologic involvement (e.g., facial nerve palsy): Part of SGMS2 spectrum in some patients, affecting evaluation and function. Frontiers

17. Genetic new (de novo) changes: Can arise for the first time in a child without family history. (General principle for autosomal dominant bone dysplasias; also inferred from case reports of sporadic presentations.) NCBI

18. Biochemical pathway vulnerability: Disrupted plasma-membrane lipid balance in osteoblasts/osteocytes affects mineral deposition. JCI Insight

19. Bone turnover imbalance: Findings of high osteoclast activity were noted in some biopsies. Wikipedia

20. Gene–environment interaction (modifier factors): Nutrition, immobility, and falls do not cause the disease but can worsen fracture risk once SGMS2-related fragility exists. (General fracture-risk principle layered onto monogenic fragility.) PMC

Symptoms

1. Bone fractures from minor trauma: Often starting in childhood; vertebrae and long bones are common sites. PMC

2. Back pain or height loss from spinal compression fractures. JCI Insight

3. Skull lumps or tenderness where calvarial lesions form (often found on imaging, sometimes palpable). Radiopaedia

4. Low bone mineral density on DEXA scans with easy fragility. PMC

5. Short stature (especially in the severe CDLSMD end). ESPE Yearbook

6. Long-bone bowing or deformity after repeated fractures (severe end). ESPE Yearbook

7. Scoliosis or curved spine from vertebral changes. PMC

8. Headache or local skull discomfort (variable; may relate to skull lesions or fractures). Radiopaedia

9. Dental issues (caries or enamel hypoplasia) reported in some series. Wikipedia

10. Raised alkaline phosphatase without clear symptoms—found on tests. Wikipedia

11. Very dense skull (cranial sclerosis) on scans in some patients. NCBI

12. Early-life fractures (neonatal period) in severe cases. ESPE Yearbook

13. Facial nerve weakness/palsy in a subset, sometimes intermittent. Frontiers

14. Generalized bone pain or limb pain after routine activities, due to micro-fractures. PMC

15. Fatigue or reduced mobility after fractures and immobilization (secondary effect). PMC

Diagnostic tests

Physical examination

1. General exam of growth and posture: The doctor measures height, weight, and body proportions and looks for short stature or a curved spine. This helps judge if dysplasia is present and how severe it is. ESPE Yearbook

2. Spine exam: The doctor checks for tenderness and height loss that suggest vertebral compression fractures. JCI Insight

3. Limb exam: Looking for bowing of long bones, pain with gentle pressure, or deformities from old fractures. ESPE Yearbook

4. Skull/scalp exam: Feeling for lumps or tender areas over the skull; these can match imaging lesions. Radiopaedia

5. Dental exam: Teeth for enamel problems or caries sometimes linked to this syndrome. Wikipedia

Manual or bedside functional tests

6. Gait and balance test: Simple walking and single-leg stance help detect pain-limited mobility and fall risk, which matters because bones are fragile. (General fracture care principle applied to CDL.) PMC

7. Back mobility testing: Gentle flexion/extension can reveal pain from vertebral crush fractures. JCI Insight

8. Upper-limb functional checks: Grip and shoulder/elbow motion look for pain from past fractures and guide therapy. (Clinical practice aligned with monogenic osteoporosis care.) PMC

Laboratory and pathological tests

9. Serum alkaline phosphatase: Can be elevated in some patients; helps characterize bone turnover. Wikipedia

10. Calcium, phosphate, vitamin D, PTH: These tests do not cause the disease but help rule out other bone conditions and correct any treatable deficits that worsen fragility. PMC

11. Bone turnover markers (e.g., P1NP, CTX): Provide a snapshot of bone formation and resorption to guide management. (Applied in monogenic osteoporosis assessments.) PMC

12. Genetic testing of SGMS2: Next-generation sequencing or targeted testing confirms the diagnosis when a pathogenic variant is found. PMC

13. Segregation testing in family members: Helps see if the variant runs with disease (typical for autosomal dominant disorders). PMC

14. Bone biopsy (selected cases): May show thin cortex, altered trabeculae, or high osteoclast activity; used when diagnosis remains unclear. Wikipedia

Electrodiagnostic tests

15. Facial nerve conduction studies (if facial weakness): Not routine for everyone, but helpful when facial palsy occurs in SGMS2 spectrum to map nerve function and recovery. Frontiers

16. EMG for limb weakness (if suspected): Only if symptoms suggest nerve or muscle issues beyond bone pain; this is uncommon but can guide therapy. Frontiers

17. Somatosensory evoked potentials (rarely): Considered if there is suspected spinal cord involvement from severe vertebral deformity; this is specialized and not standard for all patients. (Principle extrapolated for severe dysplasia/vertebral disease.) ESPE Yearbook

Imaging tests

18. Skull X-ray: Shows the classic round, ring-like calvarial “doughnut” lesions with a sclerotic rim; sometimes there is very dense skull bone. Radiopaedia

19. Skull CT or MRI: Defines the shape, density, and exact position of lesions; MRI helps assess soft tissues and any symptoms. Wikipedia

20. Spine X-rays and MRI: Look for vertebral compression fractures and spinal cord concerns in severe cases. JCI Insight

21. Long-bone radiographs: Show bowing, old fractures, and metaphyseal changes in the severe CDLSMD end of the spectrum. ESPE Yearbook

22. DEXA (bone density) scan: Confirms low bone mineral density and helps track response to treatment over time. PMC

23. Whole-body skeletal survey (childhood): Systematic X-rays can capture the full pattern—useful at baseline in complex cases. PMC

Non-pharmacological treatments (therapies & other measures)

1) Multidisciplinary care plan (genetics + endocrinology + orthopedics + physiotherapy).
Description: Because CDL affects the whole skeleton and sometimes the spine and skull, the safest care involves a coordinated plan. A geneticist confirms the SGMS2 diagnosis and guides family testing. Pediatric or adult metabolic bone specialists manage bone health, growth, and DEXA monitoring. Orthopedists manage fractures and alignment. Physical therapists build safe strength and balance. Dentists/ophthalmologists check dental enamel and screen for glaucoma where reported. Education on safe activity, fall prevention, calcium/vitamin D intake, and medication timing is essential. Clear documentation of fracture history and baseline DEXA helps track progress; periodic reassessment adapts the plan as the child grows or an adult’s risks change.
Purpose: Reduce fracture risk and complications; individualize care.
Mechanism: Team-based risk reduction and early intervention across systems. PMC+1

2) Fracture prevention education and home safety.
Description: Teach safe lifting, avoiding high-impact twists, removing loose rugs, using handrails, good lighting, and hip protectors where appropriate. School and workplace plans should allow activity with supervision and rest breaks.
Purpose: Lower fall and fracture risk day-to-day.
Mechanism: Reduces fall probability and impact forces on fragile bone. NCBI

3) Individualized physical therapy (low-impact strength & balance).
Description: Start supervised programs that emphasize posture, core strength, hip abductor strength, and balance drills (e.g., tandem stance), plus aquatic therapy for low-load conditioning. Increase gradually.
Purpose: Improve muscle support and balance to protect bones.
Mechanism: Stronger muscles and better proprioception reduce fall energy and shear on bone. NCBI

4) Weight-bearing as tolerated (guided).
Description: Age-appropriate walking, standing games, and light step-ups build bone stimulus without jumps or high axial loads.
Purpose: Encourage physiologic bone remodeling.
Mechanism: Mechanical loading stimulates osteoblast activity (Wolff’s law). NCBI

5) Spine care & posture training.
Description: Teach neutral-spine mechanics for lifting and sitting. Use ergonomic chairs and backpacks <10–15% of body weight; consider bracing only when prescribed.
Purpose: Protect vertebrae and slow deformity.
Mechanism: Reduces flexion-related compressive forces on weak vertebral bodies. NCBI

6) Assistive devices during healing.
Description: Short-term canes, walkers, or protective splints during recovery from fractures to avoid re-injury.
Purpose: Safe mobility and pain reduction.
Mechanism: Off-loading reduces stress at fracture or deformity sites. NCBI

7) Fall-proof footwear and orthotics.
Description: Use supportive shoes with good grip; custom orthotics if foot alignment is poor.
Purpose: Improve stability and gait.
Mechanism: Better ground contact lowers slip risk and ankle inversion. NCBI

8) Nutrition optimization (dietary calcium, protein, vitamin D).
Description: Aim for guideline-level calcium from foods plus adequate protein and vitamin-D-rich foods; supplements only if intake or levels are low, as advised by clinicians.
Purpose: Provide building blocks for bone.
Mechanism: Calcium, protein, and vitamin D support mineralization and remodeling. NCBI

9) Dental care & enamel protection.
Description: Because dental anomalies are reported in some patients, arrange early dental evaluation, fluoride, sealants, and gentle technique to avoid jaw stress.
Purpose: Preserve oral health and nutrition.
Mechanism: Prevents caries/enamel wear that can accompany bone dysplasias. Wikipedia

10) Ophthalmology screening when indicated.
Description: If family reports glaucoma in relatives with CDL, consider baseline and periodic checks.
Purpose: Early detection of pressure-related optic damage.
Mechanism: Screening identifies treatable eye disease linked in case reports. Wikipedia

11) Safe sport substitution.
Description: Favor swimming, cycling on flat terrain with helmet, and Pilates-style core work; avoid contact sports, trampolines, and heavy plyometrics unless cleared.
Purpose: Stay active while minimizing fracture risk.
Mechanism: Low-impact aerobic loading with minimal fall energy. NCBI

12) Sunlight hygiene (vitamin D).
Description: Short, safe mid-morning or late-afternoon sun exposure following local dermatology advice; measure 25-OH vitamin D when clinically indicated.
Purpose: Support vitamin D status.
Mechanism: Cutaneous vitamin D synthesis improves calcium absorption. NCBI

13) Smoking and alcohol avoidance.
Description: Counsel teens/adults to avoid smoking and heavy alcohol because both harm bone quality.
Purpose: Remove modifiable bone toxicants.
Mechanism: Smoking increases bone resorption; alcohol impairs osteoblasts and increases falls. NCBI

14) Safe lifting & transfer training for families.
Description: Teach parents/caregivers how to lift children with fragility without twisting or sudden axial load; use transfer belts if needed.
Purpose: Prevent at-home injuries.
Mechanism: Minimizes compressive and torsional forces on long bones/spine. NCBI

15) School and workplace accommodations.
Description: Seating, extra time between classes, elevator access, modified PE, remote options during fracture recovery.
Purpose: Maintain participation and reduce risk.
Mechanism: Environmental adaptation lowers exposure to falls and fatigue. NCBI

16) Psychological support.
Description: Offer counseling to manage anxiety around activity and fractures; connect families with rare-disease communities.
Purpose: Improve adherence and wellbeing.
Mechanism: Coping skills encourage safe, consistent rehab. Orpha

17) Medication-safety review.
Description: Clinicians should review drugs that can weaken bone (e.g., chronic glucocorticoids) or increase falls (sedatives) and try safer alternatives.
Purpose: Reduce iatrogenic bone loss and falls.
Mechanism: Minimizes pharmacologic drivers of fragility. NCBI

18) DEXA and radiographic surveillance.
Description: Use pediatric norms for children. Track spine and hip BMD, vertebral compression, and calvarial lesions as clinically indicated.
Purpose: Measure response and guide therapy.
Mechanism: Objective metrics prompt timely changes in care. NCBI

19) Pre-op planning & bone-friendly anesthesia/positioning.
Description: During any surgery, careful padding and gentle transfers avoid iatrogenic fractures.
Purpose: Prevent peri-operative injuries.
Mechanism: Reduces external forces on fragile skeletal sites. NCBI

20) Genetic counseling.
Description: Explain autosomal dominant inheritance and options for family testing and future pregnancies.
Purpose: Informed decisions and early detection.
Mechanism: Identifies at-risk relatives for monitoring and early care. NCBI

---

Drug treatment

Important: None of the medicines below are FDA-approved specifically for CDL. They are FDA-approved for osteoporosis and related conditions and are sometimes used off-label to manage bone fragility in rare dysplasias under specialist care. Dosing must be individualized by your clinician.

1) Alendronate (Fosamax/Binosto; oral bisphosphonate).
Long description (~150 words): Alendronate is a first-line antiresorptive that binds to bone mineral and inhibits osteoclasts, slowing bone breakdown. Adult regimens often use 70 mg once weekly (tablet or effervescent Binosto), taken fasting with water and staying upright for ≥30 minutes to prevent esophageal irritation. It reduces vertebral and hip fractures in postmenopausal osteoporosis and increases bone mass; in children with primary bone disorders it may be considered by specialists with careful monitoring. Typical adverse effects include GI upset, musculoskeletal pain, and rare osteonecrosis of the jaw or atypical femur fractures with long-term use; correct calcium/vitamin D deficiency before starting.
Class: Bisphosphonate antiresorptive. Dosage/Time: Common adult dose 70 mg once weekly; pediatric/rare-disease dosing is specialist-driven. Purpose: Reduce fracture risk by suppressing resorption. Mechanism: Nitrogen-containing bisphosphonate inhibits farnesyl pyrophosphate synthase in osteoclasts → apoptosis → lower bone turnover. Notable side effects: GI irritation, hypocalcemia, rare ONJ/AFF. FDA Access Data+2FDA Access Data+2

2) Risedronate (Actonel/Atelvia; oral).
Description: Similar to alendronate; weekly (35 mg) or delayed-release Atelvia after breakfast. Shown to reduce vertebral and some non-vertebral fractures in osteoporosis.
Class: Bisphosphonate. Dosage/Time: 35 mg weekly (immediate release) or 35 mg weekly delayed-release with food per label. Mechanism/Purpose: Inhibits osteoclast-mediated resorption to improve BMD and reduce fractures. Side effects: GI symptoms; rare ONJ/AFF; caution in renal disease. FDA Access Data+2FDA Access Data+2

3) Ibandronate (Boniva; oral monthly or IV every 3 months).
Description: An oral monthly or IV quarterly bisphosphonate that reduces vertebral fractures; effect on hip fracture is less certain.
Class: Bisphosphonate. Dosage/Time: 150 mg oral monthly or 3 mg IV every 3 months; avoid severe renal impairment. Side effects: GI upset (oral), flu-like symptoms (IV), rare ONJ/AFF. FDA Access Data+1

4) Zoledronic acid (Reclast; once-yearly IV in adults).
Description: A potent IV bisphosphonate used yearly (or every 2 years for prevention) in adults; pediatric protocols differ and are specialist-only. It reduces vertebral, hip, and non-vertebral fractures in osteoporosis; hydration and renal monitoring are essential.
Class: Bisphosphonate. Dosage/Time: 5 mg IV yearly (adult label). Side effects: Acute-phase reaction (fever/myalgia), hypocalcemia, renal effects; rare ONJ/AFF. FDA Access Data+1

5) Pamidronate (Aredia; IV).
Description: An older IV bisphosphonate used in pediatric osteogenesis imperfecta and other fragility states under specialist care; improves vertebral shape and reduces fractures in some pediatric cohorts (off-label). Requires slow infusion and renal monitoring.
Class: Bisphosphonate. Dosage/Time: Specialist-directed cycles IV. Side effects: Flu-like symptoms, hypocalcemia, electrolyte shifts; renal precautions. FDA Access Data+1

6) Denosumab (Prolia; subcutaneous every 6 months).
Description: A monoclonal antibody against RANKL that suppresses osteoclast formation and activity. It increases BMD and reduces vertebral, hip, and non-vertebral fractures in approved populations. In children and some rare bone disorders, safety concerns exist (risk of rebound hypercalcemia after stopping; pediatric OI studies reported serious events), so pediatric/rare-disease use must be expert-led with plans for transition.
Class: RANKL inhibitor antiresorptive. Dosage/Time: 60 mg SC every 6 months (adult label). Side effects: Hypocalcemia, infections, dermatitis, rare ONJ/AFF; rebound bone loss if abruptly discontinued. FDA Access Data+1

7) Teriparatide (PTH 1–34; Forteo or generics).
Description: An anabolic (bone-building) agent given daily by subcutaneous injection, typically for up to 2 years. It stimulates osteoblasts and increases BMD, especially in the spine; often used after or before antiresorptives in high-risk adults. Contraindications and tumor warnings from rodent data apply; correct vitamin D and calcium before use.
Class: Parathyroid hormone analog (anabolic). Dosage/Time: 20 µg SC daily (adult label). Side effects: Hypercalcemia, dizziness, leg cramps, nausea. FDA Access Data+1

8) Teriparatide injection (authorized generics/newer devices).
Description: Device-specific teriparatide products carry similar labeling with instructions for safe pen use and storage.
Class/Dose: As above. Notes: Emphasizes correct device handling to ensure dose accuracy. FDA Access Data

9) Abaloparatide (Tymlos; daily SC).
Description: A PTHrP analog with anabolic effects, used for up to 2 years in high-risk adults; often followed by an antiresorptive to “lock in” gains.
Class: Anabolic agent (PTHrP analog). Dosage/Time: 80 µg SC daily. Side effects: Hypercalciuria, dizziness, injection site reactions; similar class warnings. FDA Access Data+1

10) Romosozumab (Evenity; monthly SC for 12 months).
Description: A sclerostin-inhibiting antibody with dual effects: increases bone formation and decreases resorption. Given as two injections monthly for 12 months, then transition to an antiresorptive. Carries a boxed cardiovascular warning (MI/stroke risk); assess risk before use.
Class: Bone-forming monoclonal antibody (sclerostin inhibitor). Dosage/Time: 210 mg SC monthly for 12 months. Side effects: Arthralgia, injection reactions; CV risk warning. FDA Access Data+1

11) Calcitonin-salmon (Miacalcin/Fortical; intranasal/SC).
Description: A less-potent antiresorptive sometimes used when other options are unsuitable; fracture-reduction data are limited and there is a signal for increased malignancy risk with long-term intranasal use, so specialists use it sparingly.
Class: Antiresorptive peptide. Dosage/Time: Nasal 200 IU daily or SC per label (adults). Side effects: Rhinitis, nausea; malignancy signal noted on label. FDA Access Data+1

12) Alendronate oral solution/effervescent (for swallowing issues).
Description: Alternative formulations (e.g., Binosto effervescent) exist for patients unable to swallow tablets, with the same administration cautions about fasting and staying upright.
Class: Bisphosphonate. Notes: Follow product-specific mixing and timing. FDA Access Data+1

13) Risedronate delayed-release (Atelvia; taken after breakfast).
Description: Designed for dosing after food, which may help some patients tolerate therapy better while maintaining antiresorptive effects.
Class: Bisphosphonate. Side effects: Similar to class; counsel on proper intake. FDA Access Data

14) Ibandronate IV (for GI intolerance to oral therapy).
Description: Quarterly IV dosing avoids upper-GI side effects and adherence issues with oral regimens.
Class: Bisphosphonate. Notes: Renal function checks required. FDA Access Data

15) Zoledronic acid alternative label details (safety).
Description: Labels emphasize hydration, creatinine clearance thresholds, and caution in aspirin-sensitive patients. These safety steps are crucial in rare bone fragility states.
Class: Bisphosphonate. Key label points: Renal contraindications; acute-phase reactions. FDA Access Data+1

16) Denosumab current labeling (contraindications & warnings).
Description: Modern labels stress correcting hypocalcemia first, dental evaluation in high-risk patients, and planning for transition when stopping to avoid rebound fractures.
Class: RANKL inhibitor. Notes: Hypocalcemia contraindication; dental/ONJ precautions. FDA Access Data

17) Teriparatide device labeling (safe use).
Description: Pen-device instructions reduce dosing errors and contamination; adherence improves outcomes.
Class: Anabolic. Notes: Daily self-administration education is essential. FDA Access Data

18) Abaloparatide label updates.
Description: Label and CMC updates exist; clinicians should check the latest FDA label before prescribing.
Class: Anabolic. Notes: Same daily SC dosing; follow up with antiresorptive. FDA Access Data+1

19) Calcitonin injection (if nasal not tolerated).
Description: Injectable calcitonin is rarely used; fracture-reduction evidence is limited; reserve for specific cases per label.
Class: Antiresorptive. Notes: Counsel on limited efficacy data. FDA Access Data

20) Pamidronate contemporary label (safety notes).
Description: Modern SPL entries reiterate electrolyte shifts and renal considerations; pediatric use is off-label and specialist-only.
Class: Bisphosphonate (IV). Notes: Monitor Ca/Mg/Phos; slow infusions. FDA Access Data

---

Dietary molecular supplements

Note: Supplements are not FDA-approved to treat CDL. They may support general bone health if a deficiency exists. Doses below are typical adult ranges; pediatric dosing differs. Always test and individualize.

1) Vitamin D3 (cholecalciferol).
Long description (~150 words): Vitamin D helps the gut absorb calcium and phosphate and supports mineralization. Many people with fragility have low 25-OH-D; clinicians often target sufficiency and then maintain with daily/weekly dosing. Too much vitamin D can cause high calcium and kidney issues, so levels should guide dosing.
Dose: Often 800–2000 IU/day for adults to maintain, individualized by levels. Function/mechanism: Improves calcium absorption and bone mineralization. NCBI

2) Calcium (prefer food first; citrate if supplement needed).
Description: Calcium is a structural mineral; total daily intake typically 1000–1300 mg (diet + pills) in adults; supplements considered if dietary intake is low. Take away from bisphosphonates.
Mechanism: Provides substrate for hydroxyapatite crystals. FDA Access Data

3) Protein (adequate daily intake).
Description: Protein (with essential amino acids) supports collagen matrix and muscle strength; ensure sufficient intake via diet; supplements only if diet is inadequate.
Mechanism: Provides amino acids for bone matrix and muscles that protect bone. NCBI

4) Magnesium.
Description: Cofactor in vitamin D metabolism and bone matrix; deficiency impairs mineralization.
Dose: Commonly 200–400 mg/day adult supplement if dietary intake is low. Mechanism: Supports enzyme systems in bone remodeling. NCBI

5) Vitamin K2 (menaquinone).
Description: Helps γ-carboxylate osteocalcin for mineral binding; evidence is mixed, so use only if advised.
Mechanism: Aids osteocalcin activation. NCBI

6) Collagen peptides.
Description: Supply glycine/proline/lysine for collagen; may support bone matrix and joint comfort as part of diet.
Mechanism: Provides substrate for organic bone matrix. NCBI

7) Omega-3 fatty acids.
Description: Anti-inflammatory dietary fats that may support musculoskeletal health and reduce fall-related pain perception; food sources preferred.
Mechanism: Modulate inflammatory pathways that can affect bone turnover. NCBI

8) Silicon (orthosilicic acid).
Description: Trace element involved in collagen cross-linking and mineralization; data are limited; consider only under guidance.
Mechanism: May support bone matrix quality. NCBI

9) Zinc.
Description: Cofactor for collagen synthesis and alkaline phosphatase; deficiency impairs growth and healing.
Mechanism: Supports osteoblast function and matrix enzymes. NCBI

10) Boron.
Description: Trace element that can influence mineral and vitamin D metabolism; evidence remains preliminary—avoid high doses.
Mechanism: May modulate calcium and vitamin D handling. NCBI

---

Drugs as immunity booster / regenerative / stem-cell–related

Clear note: There are no FDA-approved stem-cell drugs for treating CDL or generalized osteoporosis. The items below are bone-anabolic or supportive therapies used for fragility in high-risk adults, and any “immune” benefit is indirect. Use only under specialist care.

1) Teriparatide (PTH 1–34).
~100 words: Daily anabolic therapy that stimulates new bone formation, used for up to 2 years then usually followed by an antiresorptive to maintain gains. Dose: 20 µg SC daily (adult). Function/Mechanism: Activates PTH receptors intermittently → osteoblast stimulation and increased bone mass. FDA Access Data

2) Abaloparatide (PTHrP analog).
~100 words: Similar to teriparatide with daily dosing and post-course consolidation using antiresorptives; choice depends on patient profile and access. Dose: 80 µg SC daily. Function/Mechanism: PTHrP receptor activation → osteoblast anabolism. FDA Access Data

3) Romosozumab (sclerostin inhibitor).
~100 words: Monthly for 12 months; increases bone formation and decreases resorption; screen for cardiovascular risk before treatment. Dose: 210 mg SC monthly × 12 months. Function/Mechanism: Blocks sclerostin to release Wnt signaling for osteoblast activity. FDA Access Data

4) Denosumab (RANKL inhibitor).
~100 words: Not regenerative but strongly antiresorptive; sometimes used after an anabolic course. Requires plan for transition to avoid rebound bone loss. Dose: 60 mg SC every 6 months. Function/Mechanism: Inhibits osteoclast formation/activity by blocking RANKL. FDA Access Data

5) Calcitonin-salmon.
~100 words: Modest antiresorptive with limited role; consider only when other options are unsuitable; note malignancy signal on labels. Dose: 200 IU intranasal daily or SC per label. Function/Mechanism: Directly inhibits osteoclast activity. FDA Access Data

6) Investigational cell-based approaches (context only).
~100 words: Mesenchymal stromal cell or BMP-based strategies are being researched for focal bone defects but are not approved drugs for systemic fragility or CDL; any such use should be limited to regulated trials. Function/Mechanism: Attempt to enhance osteogenesis locally. PMC

---

Surgeries (what they are and why done)

1) Fracture fixation (plates, nails, casts).
Procedures: Standard orthopedic fixation or casting tailored to bone size/quality; careful handling to avoid new fractures. Why done: Align and stabilize broken bones so they heal straight and strong. NCBI

2) Guided growth or corrective osteotomy (limb deformity).
Procedures: Temporary hemiepiphysiodesis (guided growth) in children or osteotomy with plating/rodding in older patients to correct varus/valgus or rotational deformity. Why done: Improve alignment, gait, and pain; reduce future fracture risk. NCBI

3) Spinal surgery for severe deformity or instability.
Procedures: Bracing first; if progressive, posterior fusion/instrumentation by experienced pediatric spine teams. Why done: Protect spinal cord, improve posture and lung space, reduce pain. NCBI

4) Cranioplasty (selected symptomatic calvarial lesions).
Procedures: Rarely, if skull lesions are symptomatic, deforming, or complicate other care, a neurosurgeon may contour or reconstruct. Why done: Address pain, protection, or contour concerns. Orpha

5) Dental procedures with bone-aware technique.
Procedures: Restorations, sealants, or orthodontic work using gentle forces; invasive procedures planned carefully if on antiresorptives. Why done: Preserve function, prevent caries, and support nutrition. Wikipedia

---

Preventions

1. Keep vitamin D and calcium in the healthy range with clinician guidance. NCBI

2. Stay active with low-impact exercise; avoid high-risk impact and twisting. NCBI

3. Use home fall-prevention: good lighting, handrails, remove trip hazards. NCBI

4. Wear supportive, non-slip footwear; consider orthotics if advised. NCBI

5. Do balance/strength training and core posture practice. NCBI

6. Avoid smoking and heavy alcohol; review meds that harm bone. NCBI

7. Maintain a healthy body weight and adequate protein. NCBI

8. Use hip and spine protection strategies during risky tasks. NCBI

9. Schedule regular DEXA and clinic reviews to adjust therapy. NCBI

10. Ensure school/work accommodations to reduce falls and fatigue. NCBI

---

When to see a doctor

See a bone specialist promptly if any of these occur: new fracture or severe bone pain, sudden back pain or height loss (possible vertebral fracture), frequent falls, delayed fracture healing, new limb deformity, progressive spinal curve, dental enamel problems affecting eating, visual changes (screen for glaucoma if family reports it), medication side effects (jaw pain, thigh pain, low calcium symptoms), or pregnancy planning in an affected family (genetic counseling). CDL is rare—early specialist input improves safety and planning. NCBI+1

---

What to eat” and “what to avoid

Eat:

1. Dairy or fortified dairy alternatives for calcium. FDA Access Data

2. Fish with bones (sardines), leafy greens, almonds, sesame. FDA Access Data

3. Vitamin-D–rich foods (fatty fish, fortified milk). FDA Access Data

4. Lean proteins (eggs, poultry, legumes) to support matrix and muscle. NCBI

5. Fruits/vegetables for magnesium and potassium balance. NCBI

Avoid/limit:

1. Sugary drinks and ultra-processed food that displace nutrient-dense options. NCBI
2. Excess caffeine/cola (avoid with calcium tablets due to absorption issues). FDA Access Data
3. High-salt diets (increase urinary calcium loss). NCBI
4. Heavy alcohol and smoking (harms bone). NCBI
5. Grapefruit/other interacting foods when labels warn (follow drug-specific guidance). FDA Access Data

---

Frequently asked questions

1) What exactly is CDL?
A rare genetic bone fragility disorder with ring-shaped skull lesions and low bone density, sometimes with spine/long-bone dysplasia (CDL-SMD). NCBI

2) What gene is involved?
Most known families have variants in SGMS2, which disrupts sphingomyelin synthesis needed for bone mineralization. PMC

3) How is it inherited?
Autosomal dominant—one changed copy is enough; family testing is recommended. NCBI

4) When do fractures start?
Often in childhood; in severe forms, fractures can start in the newborn period. NCBI

5) Are the skull “doughnut” spots dangerous?
They are distinctive radiologic signs; most are benign, but surgeons may evaluate if symptomatic or deforming. Orpha

6) Is there a cure?
No single cure; treatment focuses on preventing fractures, improving bone strength, and correcting deformities. NCBI

7) Do osteoporosis medicines help?
Specialists often use bisphosphonates or anabolic agents off-label to improve BMD and reduce fractures; choices depend on age, risks, and goals. FDA Access Data+1

8) Are there stem-cell treatments?
No FDA-approved stem-cell drugs for CDL; cell-based approaches remain investigational. PMC

9) What about denosumab?
Effective antiresorptive in adults; pediatric/rare-disease use needs caution due to rebound risks and pediatric safety concerns—specialist decision. FDA Access Data

10) How long do I take therapy?
Duration varies: IV bisphosphonates are cycled; teriparatide/abaloparatide usually up to 2 years; romosozumab for 12 months—then consolidation plans follow. FDA Access Data+2FDA Access Data+2

11) What tests confirm CDL?
Clinical exam, X-rays (skull lesions), DEXA for BMD, and molecular testing for SGMS2. NCBI

12) Does diet matter?
Yes—adequate calcium, protein, and vitamin D support bone; supplements only to correct deficiencies. FDA Access Data

13) Can children exercise?
Yes—tailored low-impact programs build muscle and balance while avoiding high-risk impact. NCBI

14) What dental or eye checks are needed?
Dental assessments for enamel/caries and ophthalmology screening when family history suggests glaucoma. Wikipedia

15) What’s the outlook?
With early diagnosis, fracture prevention, and appropriate therapy, many patients improve bone strength and function; severity varies by family and mutation. PMC

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 08, 2025.

PDF Documents For This Disease Condition References